GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (NAS:EMBC) » Definitions » EPS (Diluted)

Embecta (Embecta) EPS (Diluted) : $0.95 (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Embecta EPS (Diluted)?

Embecta's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.35. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.95.

Embecta's EPS (Basic) for the three months ended in Dec. 2023 was $0.35. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.96.

Embecta's EPS without NRI for the three months ended in Dec. 2023 was $0.35. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $1.87.

During the past 12 months, Embecta's average EPS without NRIGrowth Rate was -32.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Embecta's highest 3-Year average EPS without NRI Growth Rate was -14.20% per year. The lowest was -26.40% per year. And the median was -20.30% per year.


Embecta EPS (Diluted) Historical Data

The historical data trend for Embecta's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta EPS (Diluted) Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
EPS (Diluted)
7.58 7.50 7.28 3.89 1.22

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.24 0.26 0.10 0.35

Competitive Comparison of Embecta's EPS (Diluted)

For the Medical Instruments & Supplies subindustry, Embecta's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embecta's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embecta's PE Ratio distribution charts can be found below:

* The bar in red indicates where Embecta's PE Ratio falls into.



Embecta EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Embecta's Diluted EPS for the fiscal year that ended in Sep. 2023 is calculated as

Diluted EPS (A: Sep. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(70.4-0)/57.758
=1.22

Embecta's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(20.1-0)/57.632
=0.35

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embecta  (NAS:EMBC) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Embecta EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Embecta's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (Embecta) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Executives
David F Melcher director 1650 TYSONS BOULEVARD, SUITE 1700, MCLEAN VA 22102
Devdatt Kurdikar officer: President and CEO ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jacob Elguicze officer: Chief Financial Officer ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Jeffrey Z Mann officer: SVP, GC, Head Corp. Dev., Secy 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Jean Casner officer: Chief Human Resources Officer 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Ajay Kumar officer: SVP and CHRO C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
Shaun Curtis officer: SVP, Global Manuf./Sup. Chain C/O EMBECTA CORP., ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417
David Albritton director ONE BECTON DRIVE, FRANKLIN LAKES NJ 07417-1880
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Brian Capone officer: VP, CAO & Corp. Controller 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Carrie L Anderson director 3005 HIGHLAND PARKWAY, SUITE 200, DOWNERS GROVE IL 60515
Claire Pomeroy director BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Christopher R Reidy director ONE ADP BLVD, ROSELAND NJ 07068
Robert J. Hombach director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015